1. Allander T. Cloning of a human parvovirus by molecular screening of respiratory tract samples / Allander T., Tammi M. T., Eriksson A, Bjerkner A., Tiveljung-Lindell A., Andersson B. / Proc. Natl. Acad. Sci. U. S. A. -2005. -Vol.102. -P.12891-12896.
2. Anderson M. J. Experimental parvoviral infection in humans / Anderson M. J., Higgins P. G., Davis L. R., Willman J. S., Jones S. E., Kidd I. M., Pattison J. R., Tyrrell D. A. // J. Infect. Dis. -1985. -Vol. 152. -P. 257-265.
3. Ballou W.R. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C / Ballou W.R. , Reed J.L., Noble W., Young N.S., Koenig S. //J. Infect. Dis. -2003. -Vol. 187. -P.675-678.
4. Butchko A.R. Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women / Butchko A.R., Jordan J.A. // J. Clin. Microbiol. - 2004. -Vol. 42. -P. 31913195.
5. Crane J. Parvovirus B 19 infection in pregnancy / Crane J., Mundle W., Boucoiran I.; Maternal Fetal Medicine Committee, Gagnon R., Bujold E., Basso M. et al // J Obstet Gynaecol Can. -2014. -Vol. 36. - № 12. -Р. 1107-16.
6. Elnifro E. Seroprevalence of parvovirus B19 among pregnant women in Tripoli, Libya / Elnifro E., Nisha A.K., Almabsoot M., Daeki A., Mujber N., Muscat J. // J. Infect. Dev. Ctries. -2009. -Vol. 3. -P. 218-220.
7. Enders M. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany / Enders M., Weidner A., Enders G. // Epidemiol. Infect. -2007. -Vol. 135. -P. 563-569.
8. Enders M. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases / Enders M., Weidner A., Zoellner I., Searle K., Enders G. // Prenat. Diagn. - 2004. -Vol. 24, № 7. -Р.513-518.
9. Jones M. S. New DNA viruses identified in patients with acute viral infection syndrome / Jones M. S., Kapoor A., Lukashov V.V., Simmonds P., Hecht F., Delwart E. // J. Virol. -2005. -Vol.79. -P.8230-8236.
10. Kaufmann B. The structure of human parvovirus B19 / Kaufmann B., Simpson A.A., Rossmann M.G. // Proc. Natl. Acad. Sci. U. S. A. -2004. -Vol. 101. -P.11628-11633.
11. Kelly H.A. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world / Kelly H.A., Siebert D., Hammond R., Leydon J., Kiely P., Maskill W. // Epidemiol. Infect. -2000. -Vol. 124. -P. 449-457.
12. Koch W.C. Fifth (human parvovirus) and sixth (herpesvirus 6) diseases / Koch W.C. // Curr. Opin. Infect. Dis. -2001. -Vol. 14. -P.343-356.
13. Koppelman M.H.G.M. Quantitative real-time detection of parvovirus B19 DNA in plasma / Koppelman M.H.G.M., Cuypers H.T.M., Emrich T., Zaaijer H.L. // Transfusion. -2004. -Vol 44, № 1. -P. 97-103.
14. Lassen J. Parvovirus B19 infection in pregnancy and subsequent morbidity and mortality in offspring / Lassen J., Bager P., Wohlfahrt J., Bottiger B., Melbye M. // Int J Epidemiol. -2013. -Vol. 42. -№ 4. -Р. 1070-1076.
15. Lindenburg I.T. Long-term neurodevelopmental and cardiovascular outcome after intrauterine transfusions for feyal anaemia: a review / Lindenburg I.T., van Klink J.M., Smits-Wintjens V.E., van Kamp I.L., Oepkes D., Lopriore E. // Prenat Diagn. -2013. -Vol. 33. -№ 9. -Р. 815-822.
16. Matsuda H. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin/ Matsuda H., Sakaguchi K., Shibasaki T., Takahashi H., et al. // J. Perinat. Med. - 2005. -Vol. 33, № 6. -Р. 561-563.
17. Morgan-Capner P. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy) / Morgan-Capner P., Crowcroft N.S. // Commun. Dis. Public Health - 2002. -Vol. 5. -P. 59-71.
18. Mossong J. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection / Mossong J., Hens N., Friederichs V., Davidkin I., Broman M., et al. // Epidemiol. Infect. - 2008. -Vol. 136. -P.1059-1068.
19. Nagel H.T. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection / Nagel H.T., de Haan T.R., Vandenbussche F.P., Oepkes D., Walther F.J. // Obstet. Gynecol. - 2007. -Vol. 109. -P. 42-47.
20. Nicolay N. Clinical and epidemiological aspects of parvovirus B19 infections in Ireland, January 1996-June 2008 / Nicolay N., Cotter S. // Euro Surveill. - 2009. -Vol. 14. -P.1-5.
21. Norja P. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue / Norja P., Hokynar K., Aaltonen L.M., Chen R., Ranki A. et al // Proc. Natl. Acad. Sci. U. S. A. -2006. -Vol. 103. -P.7450-7453.
22. Nunoue T. Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis / Nunoue T., Kusuhara K., Hara T. // Pediatr. Infect. Dis. J. - 2002. -Vol. 21, № 12. -Р. 1133-1136.
23. O'Malley A. Parvovirus infects cardiac myocytes in hydrops fetalis / O'Malley A., Barry-Kinsella C., Hughes C., Kelehan P., Devaney D., et al. // Pediatr. Dev. Pathol. - 2003. -Vol. 6, № 5. -Р. 414-420.
24. Palmer G.A. A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation / Palmer G.A., Brogdon J.L., Constant S.L., Tattersall P. // J. Virol. - 2004. -Vol. 78. -P.11011108.
25. Riipinen A. Parvovirus b19 infection in fetal deaths / Riipinen A., Vaisanen E., Nuutila M., Sallmen M., Karikoski R., et al. // Clin. Infect. Dis. -2008. -Vol. 47, № 12. -Р. 1519-1525.
26. Savarese I. Atypical manifestations of congenital parvovirus B19 infection / Savarese I., De Carolis M.P., Costa S., De Rosa G., De Carolis S., et al. // Eur. J. Pediatr. - 2008. -Vol. 167, № 12. -Р. 1463-1466.
27. Servant-Delmas A. Advances in human B19 erythrovirus biology / Servant-Delmas A., Lefrere J-J., Morinet F., Pillet S., // J. Virol. -2010. -Vol. 84, № 19 -Р. 9658-9665.